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Editorials
Consensus is yet to be reached on the optimal approach to screening
AUSTRALIANS have a 1 in 21 lifetime risk of developing
colorectal cancer.1 The incidence of the disease and mortal-
ity resulting from it can be reduced by population-based
screening programs, as has been demonstrated in several
large randomised controlled trials of faecal occult blood
testing (FOBT).2 The Bowel Cancer Screening Pilot Pro-
gram currently unde  way in Queensland, South Australia
and Victoria is assessing the practical application of FOBT.
While screening of asymptomatic, average-risk individuals
for colorectal cancer is advocated by many authorities
worldwide (including the National Health and Medical
Research Council [NHMRC] in Australia1), uncertainty
remains as to the screening test of choice. The numerous
publications on the subject are indeed like jigsaw pieces
waiting to be put together to reveal the complete picture. In
addition to FOBT, the NHMRC-recommended screening
options for asymptomatic, average-risk individuals include
flexible sigmoidoscopy (FS), and it is timely to review its
role here.
Colonoscopic studies on asymptomatic people show that
60% of adenomas and cancers occur in the distal colon and
are potentially detectable by sigmoidoscopy. Case–control
studies have shown that sigmoidoscopy can reduce the risk
of subsequent fatal distal colorectal cancer by up to 60%,
translating to an approximate 30% reduction in overall
colon cancer mortality.3 Direct evidence of the magnitude of
benefit from randomised controlled trials that are currently
under way is awaited. A 5-yearly screening interval is
recommended, based on data from these ongoing studies
(which suggest that benefit from sigmoidoscopy extends up
to 10 years) and on studies of repeat colonoscopy (which
show that significant neoplasia is very uncommon 5 years
after polypectomy or a normal examination).
What are the performance characteristics of FS? The
procedure is typically done in an unsedated patient after
administration of an enema and takes 5–10 minutes to
perform. At our institution, generally eight procedures are
done by one operator over 2 hours. The instrument is
advanced as far as is tolerated with reasonable comfort
(mean insertion depth, 60 cm; range, 30–110 cm4) with
biopsy or removal of polyps performed at the time. The
finding of any adenomatous polyp or other suspicious lesion
prompts further evaluation with colonoscopy. Fifteen per-
cent of such screenings result in referral for colonoscopy.5
However, some have suggested that diminutive adenomas
may not require follow-up — a policy that might reduce
colonoscopy referrals to 5% of screenings.6 FS is a safe
procedure, with a reported colonic perforation rate of about
1 in 50 000.7 Outpatient colonoscopy, which includes thera-
peutic procedures, has a perforation rate of about 1 in
1000.8
Concerns are commonly raised about the potential miss
rate of FS for lesions in the proximal colon beyond the reach
of the instrument and of small lesions that are overlooked in
the areas examined. Many heterogeneous studies have
addressed the issues of missed proximal colonic lesions and
of what distal colonic findings should trigger colonoscopic
follow-up. The likelihood of a proximal advanced polyp (ie,
one with pathological features that increase malignant
potential, such as size or villous architecture) increases with
a more advanced distal finding. In the absence of any distal
adenoma, 2%–5% of asymptomatic people screened will
have isolated proximal advanced lesions.9 Whether this is
acceptable in the context of cancer screening may become
clear from prospective studies. The fact that sigmoidoscopy
may also miss lesions within the area of colon that is
examined may have implications for the screening intervals
used. It has been shown on repeat FS that polyps may be
missed in up to 20% of cases,10 while with colonoscopy a
6% miss rate for adenomas larger than 1 cm has been
reported.11 Schoen et al12 recently reported a 0.8%
advanced adenoma or cancer rate (there were 6 cancers in
9317 repeat examinations) in patients having a repeat
examination 3 years after an apparently normal examina-
tion; 80% of advanced lesions were in regions thought to
have been adequately examined previously, indicating
missed or newly evolved lesions. However, other studies
have shown that after 5 years the rate of new findings is low
enough to consider lengthening the screening interval.5
The technical aspects of FS are sufficiently clear to enable
us to define what FS can and cannot do. From the point of
view of screening, FS clearly cannot completely exclude the
presence of colon cancer in all asymptomatic people. A
distinction must be made between screening the general
population and testing the individual seeking screening. For
the former, obtaining the greatest mortality benefit safely
and at an acceptable cost to the nation is the crux of the
matter. Recently published data indicate that FS is a cost-
effective screening strategy, although colonoscopy and
annual FOBT avert a greater number of cancer deaths.13
The results of randomised controlled trials of screening FS
and colonoscopy, currently being conducted, will allow us to
make a more accurate comparison with the established data
regarding FOBT.
Participation rates in sigmoidoscopy screening (23% in
initial screening and 54% in follow-up screening at our
institution) are encouraging given the invasive nature of FS
screening.4,5 The ability of Australian gastroenterologists to
accommodate increased demand for colonoscopy, whether
as a follow-up to FOBT or FS, remains to be seen.
Pieces of the jigsaw continue to fall into place, although it
is likely to be some years before a clearly superior screening
modality is determined. The emergence of new technologies
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such as virtual colonoscopy14 and faecal genetic testing will
continue to add to the available armamentarium.
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IN SEPTEMBER 2003, the National Health and Medical
Research Council (NHMRC) approved the new Australian
Standard Vaccination Schedule recommended by the Aus-
tralian Technical Advisory Group on Immunisation
(ATAGI) (Box). The schedule includes inactivated poliomy-
elitis vaccine (IPV), varicella vaccine and seven-valent pneu-
mococcal conjugate vaccine (7vPCV) for infants and young
children. Earlier, in late 2002, routine meningococcal C
conjugate vaccine was approved and funded for children
aged 12 months, together with a cross-sectional catch-up
program for young people to the age of 19 years (media
release, Senator Kay Patterson, 24 November 2002). For
the first time since 1994 — when all vaccines recommended
on the schedule were funded for children vaccinated by both
private and public providers under the National Immunisa-
tion Strategy1 — the childhood schedule recommended by
NHMRC contains vaccines (IPV, varicella and 7vPCV) not
available free of charge to parents.
As well as adding these four vaccines to the childhood
program, the NHMRC also approved changes to the pertus-
sis vaccination schedule. Since the diphtheria–tetanus vac-
cine was replaced by a combined diphtheria–tetanus–
acellular pertussis (DTPa) vaccine at 4–5 years in 1995, the
peak age of pertussis has progressively risen to 13–18 years.2
Based on recent evidence that three doses of DTPa in the
first year of life provide good protection until the age of 6
years,3 it was decided to adjust the schedule so that the fifth
dose is now given to adolescents at 15–17 years, using an
adult-formulated vaccine (dTpa). This was done by remov-
ing the 18-month dose, thus making the 4-year dose the
fourth dose. This is not expected to lower preschoolers’
protection from pertussis,4 but should help reduce the
number of large local reactions seen when the dose was
given at 18 months.5
Inactivated poliomyelitis vaccine was recommended
because it does not cause the extremely rare (1 in 2.4 million
doses) live-vaccine-associated paralytic polio. The United
States has already changed to inactivated vaccine,6 and other
countries are considering doing so. The change to this
vaccine in Australia may take time, as it is many times more
costly than the oral vaccine and has had limited availability.
Although various combinations of IPV with diphtheria,
tetanus, acellular pertussis, Haemophilus influenzae type b
and hepatitis B vaccines are licensed in Australia,7 they are
not yet available, as the companies producing them are
uncertain of the potential market. In the interim, the
Australian Government’s National Immunisation Program
will continue to provide free oral live-attenuated poliomyeli-
tis vaccine.
In making recommendations about the inclusion of each
new vaccine in the childhood vaccination schedule, ATAGI
took into account a wide range of factors. These included:
■ vaccine safety and efficacy;
■ the preventable burden of the disease targeted by the
vaccine;
■ the ease with which the vaccine could be integrated into
the existing schedule;
■ any likely effects on herd immunity, reduction in anti-
biotic resistance or impact on disease epidemiology; and
■ cost-effectiveness and equity issues.
Some of the information used by ATAGI as the basis for
its recommendations is contained in the The Australian
immunisation handbook (8th edition), while the levels of
evidence for the new recommendations are available on the
494 MJA Vol 180 17 May 2004
EDITORIALS
